| scholarly article | Q13442814 |
| P2093 | author name string | Su Yeon Kim | |
| Márta Péntek | |||
| Petra Baji | |||
| Valentin Brodszky | |||
| László Gulácsi | |||
| HoUng Kim | |||
| Yu Young Cho | |||
| P2860 | cites work | Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis | Q26828622 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
| Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries | Q33713261 | ||
| Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
| What is the natural history of rheumatoid arthritis? | Q34254534 | ||
| Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and b | Q34269890 | ||
| Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 | ||
| Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe | Q35069447 | ||
| The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review | Q35188042 | ||
| The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study | Q35554010 | ||
| Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis | Q36062038 | ||
| Systematic review of studies of productivity loss due to rheumatoid arthritis | Q36312507 | ||
| A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre | Q36348464 | ||
| Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution | Q36778450 | ||
| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | Q37206622 | ||
| A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study | Q37206628 | ||
| Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs | Q37314038 | ||
| Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database | Q37374953 | ||
| Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review | Q37782588 | ||
| State-of-the-art: rheumatoid arthritis | Q37801492 | ||
| Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature | Q37967684 | ||
| Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? | Q38065592 | ||
| The role of biosimilars in the treatment of rheumatic diseases | Q38068691 | ||
| Clinical experience with Zarzio® in Europe: what have we learned? | Q38125609 | ||
| Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis | Q38176549 | ||
| Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries | Q38212140 | ||
| Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison | Q38212142 | ||
| Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies | Q38260217 | ||
| Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries | Q39141802 | ||
| Economic burden of long-term care of rheumatoid arthritis patients in Hungary | Q39191669 | ||
| Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey | Q43461275 | ||
| Inequities in access to biologic and synthetic DMARDs across 46 European countries | Q44191676 | ||
| Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States | Q44650428 | ||
| The burden of rheumatoid arthritis and access to treatment: health burden and costs | Q46256192 | ||
| Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy | Q46976231 | ||
| The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study | Q47856931 | ||
| Societal cost of rheumatoid arthritis patients in the US. | Q48956161 | ||
| Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. | Q53107390 | ||
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | S43-52 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Biosimilars for the management of rheumatoid arthritis: economic considerations | |
| P478 | volume | 11 Suppl 1 |
| Q33881234 | A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. |
| Q42044847 | Access to biologicals in Crohn's disease in ten European countries |
| Q50115818 | Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases |
| Q64100779 | An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis |
| Q88427603 | Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland |
| Q39403982 | Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. |
| Q92480548 | Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings? |
| Q47688424 | Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm |
| Q96306725 | Biosimilars in the management of chronic inflammatory diseases: The Dutch experience |
| Q38676104 | CT-P13 in the treatment of rheumatoid arthritis. |
| Q38953729 | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab |
| Q57191804 | Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis |
| Q92891201 | Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis |
| Q55693631 | Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. |
| Q38845478 | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. |
| Q100395102 | Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis |
| Q64926959 | Era of biosimilars in rheumatology: reshaping the healthcare environment. |
| Q92703340 | Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review |
| Q51022840 | Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. |
| Q53117938 | Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings. |
| Q38663329 | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| Q38893192 | Pharmacoeconomics of Biosimilars: What Is There to Gain from Them? |
| Q91918289 | Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece |
| Q92440871 | Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review |
| Q47807650 | Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons |
| Q39184810 | Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey |
| Q26749525 | Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health |
| Q89460342 | The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases |
| Q33665611 | The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries |
| Q26766515 | The changing landscape of biosimilars in rheumatology |
| Q30397234 | The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis |
Search more.